---
categories: 
- Database
- Release
date: 2022-08-04
title: Database release
github_url: https://github.com/vanallenlab/moalmanac-db/releases/tag/v.2022-08-04
---
Added entries:
- (FDA) _ALK-EML4_ and sensitivity to crizotinib in inflammatory myofibroblastic tumors.
- (Clinical trial) _BRCA1_ and _BRCA2_ germline variants and sensitivity to olaparib.  
- (Clinical evidence) _BRCA2_ copy number deletion and loss-of-function somatic variants and sensitivity to olaparib in uterine leiomyosarcoma.
- (Clinical evidence) _CDKN2A_ deletion and sensitivity to palbociclib in uterine leiomyosarcoma.
- (Clinical evidence) _MYOCD_ amplification as a diagnostic for strong smooth muscle differentiation in leiomyosarcoma.
- (Preclinical) _RB1_ copy number deletion and somatic variants and sensitivity to olaparib and talazoparib in prostate cancer.
- (Preclinical) _RB1_ knockout and resistance to palbociclib in prostate cancer.
- (Preclinical) _USP11_ silencing and sensitivity to olaparib in osteosarcoma.
- (Inferential) _ATRX_ copy number deletions and poor prognosis in leiomyosarcoma. 
- (Inferential) _BRCA1_ and _BRCA2_ copy number deletion and loss-of-function somatic variants and sensitivity to PARP inhibition (KU0058684, KU0058948).
- (Inferential) _CDKN2C_ deletion may confer sensitivity to CDK4/6 inhibitors. 
- (Inferential) _MAP2K4_ and _MAPK7_ copy number amplification and not sensitive to chemotherapy as well as poor prognosis in osteosarcoma.  
- (Inferential) _PDGFRA_ copy number amplification and poor prognosis in breast cancer.
- (Inferential) _PTEN_ copy number deletion and poor prognosis in uterine leiomyosarcoma. 
- (Inferential) _PTEN_ copy number deletion and sensitivity to sapanisertib in combination with alpelisib in uterine leiomyosarcoma. 